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A B S T R A C T
An open label, multi-center, 6 months observational study of new fixed combination (travoprost 0.004%/timolol 0.5%),
in order to evaluate both efficacy (intraocular pressure lowering) and tolerability (patient and investigator satisfaction)
of two dosing regimens –evening (PM) and morning (AM). After scrrening for enrollment, to 40 patients (79 eyes with
primary open angle glaucoma or ocular hypertension), new fixed combination travoprost 0.004%/timolol 0.5% was pre-
scribed once a day in the evening (PM). Patients were enrolled according to each investigator decision on indication for
travoprost 0.004%/timolol 0.5% fixed combination once a day, without washout period after previous medication.
Intraocular pressure was measured at 9 AM at all time control points: at baseline, after 1 month, after 3 months and af-
ter 6 month. After 1 month, screening for nonresponders (criteria: 20% intraocular pressure lowering) and subjects with
major side effects was performed. At second control visit, after 3 months PM dosing, intraocular pressure was measured
and patients were instructed to continue once a day the same medication, but in the morning (AM) for consequent 3
months. After 1 month, reduction in mean intraocular pressure value was 21.66%. At the visit after 3 month, the mean
intraocular pressure was 15.67±2.17 mm Hg (reduction 21.14%). 3 month after dosing regimen changed to AM (6 month
after beginning of travoprost 0.004%/timolol 0.5% combination therapy), reduction in intraocular pressure value was
19.86%. The differences (mean±standard deviation) in intraocular pressure values after 1, 3 nad 6 month were all highly
statistically significant compared to baseline values. The tolerability was evaluated in five steps (Likert scale) ranging
from unsatisfactory to excellent by both patient and investigator – taken at 3 and 6 month control visit. 95% of patients
and 100% of investigators were satisfied with the possibility of choosing dosing regimen for travoprost 0.004%/timolol
0.5% fixed combination. Travoprost 0.004%/timolol 0.5% fixed combination proved sufficient intraocular pressure con-
trol dosed either PM or AM with no statistically significant difference between two dosing regimens. Possibility to choose
between two dosing regimens gives each practitioner additional reassurance that glaucoma therapy will be individual-
ised to needs of each patient.
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Introduction
Glaucoma is potentially blinding, multifactorial optic
neuropathy characterized by progressive loss of optic
nerve tissue with associated visual field loss. Elevated
intraocular pressure is often observed in glaucomatous
eyes and is a strong risk factor for the development and
progression of glaucoma¹. Therapeutically reducing in-
traocular pressure is the only proven way to reduce the
risk of developing glaucoma as well as slowing the pro-
gression of the disease once it is present2,3–7. Topical
b-adrenergic blocking agents, such as a timolol, have
been widely accepted as a first line therapy for glaucoma
and ocular hypertension8,9. b-blockers reduce intraocular
pressure by slowing the rate of aqueous humor for-
mation10. In recent years, a new family of drugs, the
prostaglandin analogues, has become mostly prescribed.
Studies have shown that travoprost 0.004% ophtalmic
solution is a potent FP receptor agonist in human ciliary
muscle and trabecular meshwork cells11,12. Unlike b-blo-
ckers, prostaglandin analogs reduce intraocular pressure
by increasing both uveoscleral and conventional aqueous
humor outflow13. Travoprost is a prostaglandin analog
product approved for once-daily dosing in patients with
open- angle glaucoma or ocular hypertension. Travoprost
has been shown in many large-scale, multicenter clinical
trials to produce clinically relevant reductions of baseline
intraocular pressure that are better than timolol with a
safety profile comparalbe to other prostaglandin ana-
logs14,15.
As many as 40% of patients treated for glaucoma are
unable to achieve adequate control of intraocular pres-
sure with a single medication16. Patients are often pre-
scribed multiple medications from the different classes of
intraocular pressure – lowering therapies. While multi-
ple medications can achieve acceptable intraoculare pres-
sure levels for many patients, the use of more than one
dosing bottle is associated with several concerns, includ-
ing increased preservative exposure of multiple drops,
greater patient cost for multiple prescriptions, reduced
compliance, and potential washout from multiple do-
sing17. In a 6-month study of concomitant therapy with
travoprost 0.004% and timolol 0.5% in patients with
inadequatelly controlled intraocular pressure with ti-
molol 0.5% alone, has been demonstrated efficacy and
safety of this combination18. Side effects of concomitant
therapy were mild. These findings have led to the devel-
opment of a fixed combination of travoprost 0.004% and
timolol 0.5%, which has advantage because majority of
glaucoma patients require more than one medication.
When used as first-line therapy for open-angle glaucoma
and ocular hypertension, timolol is often dosed twice
daily. However, the use of a fixed dose combination of
timolol and a prostaglandin analogue in a single ophthal-
mic solution dosed once daily has been demonstrated to
provide a significant additive effect19 and has the poten-
tial to improve patient compliance. This study was de-
signed to evaluate the efficacy and tolerability of a fixed
combination ophthalmic solution of travoprost 0.004%
and timolol 0.5%, given once daily, in patients with
open-angle glaucoma or ocular hypertension and to de-
termine whether there is any significant difference
between morning (AM) or evening (PM) dosing. The pri-
mary objective was to demonstrate that morning and
evening dosing produce equivalent intraocular pressure-
-lowering effect. The secondary objective was to evaluate
patient and investigator satisfaction with two dosing reg-
imens.
Materials and Methods
This study was a multicenter, prospective, clinical ob-
servational study, open-label to both-patients and inves-
tigators. Patients eligible for inclusion were of either sex
(22 male, 18 female) and one ethnic group (all cauca-
sian), older than 18 years of age, diagnosed with either
open-angle glaucoma (37 patients) (without pseudoexfo-
liative or pigmentary glaucoma) or ocular hypertension
(3 patients), and were currently treated with a pres-
sure-lowering monotherapy (timolol 0.5%, betaxolol 0.5%,
travoprost 0.004%, latanoprost 0.005%). Patients were
enrolled according to each investigator decision on indi-
cation for travoprost 0.004%/timolol 0.5% fixed combina-
tion, without washout period after previous medication,
if IOP values at baseline with monotherapy were over 20
mm Hg. In all enrolled patients, best corrrected visual
acuity was over 0,6 on both eyes, C/D ratio over 0.8, and
anterior chamber angle grade was 3 or 4 (measured by
gonioscopy). Patients were without severe central visual
field defects on both eyes. Women of childbearing poten-
tial were excluded from the study if they were currently
pregnant, had a positive urine pregnancy test at the
screening visit, intended to become pregnant, were bre-
ast feeding, or were not using highly effective birth con-
trol measures. Patients were also excluded if they had a
history of chronic or recurrent severe inflammatory eye
disease; a history of ocular trauma within the preceding
6 months or ocular infection or inflammation within the
preceding 3 months; a history of clinically significant or
progressive retinal disease, other severe ocular pathology
that would have precluded the administration of a topical
prostaglandin analogue, or severe or serious hypersensi-
tivity to any components of the study medication; had
undergone intraocular surgery within the preceding 6
months or ocular laser surgery within the preceding 3
months; or had a best-corrected visual acuity worse than
0.6, anterior chamber angle grade 1 or 2 (measured by
gonioscopy), a C/D ratio greater than 0.8, or severe cen-
tral visual field loss in either eye. In addition, patients
could not take part if they were taking glucocorticoids or
any additional topical or systemic ocular hypotensive
medication; had a history of severe, unstable, or uncon-
trolled cardiovascular, hepatic, or renal disease or bron-
chial asthma or severe chronic obstructive pulmonary
disease.
After screening for enrollment, to 40 patients (79
eyes) with primary open angle glaucoma or ocular hyper-
tension, fixed combination travoprost 0.004%/timolol
0.5% was prescribed once a day in the evening at 8 PM
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(PM dosing regimen). No washout period was planned
for any of previous medications, because intention was to
observe clinical pattern of performance of new fixed med-
ication, without interrupting or modifying investigators
personal decision on necessity to change medication.
Intraocular pressure was measured always at 9 AM: at
baseline, and after 1, 3 and 6 months.. At second control
visit, after 3 months of PM dosing regimen, patients
were instructed to continue administration of the same
medication once a day in the morning at 8 AM (AM dos-
ing regimen) for next 3 months. After 1, 3 and 6 month
there were no nonresponders (criteria: IOP lowering
20%) and no subjects with major side effects. Minor side
effects were not reason to terminate therapy. Reported
minor side effects were: eyelashes growth (2 patients – 4
eyes) and mild hyperemia (4 patients – 8 eyes). Tolera-
bility was evaluated by the patient and the investigator
on a five-point scale, ranging from unsatisfactory to ex-
cellent, taken after 3 and 6 month travoprost 0.04%/ti-
molol 0.5% fixed combination therapy. If the tolerability
was judged as good, very good and excellent, this finding
was evaluated as satisfactory (Likert scale)20.
Doctors were satisfied with therapy when IOP droped
by 20% and if patients had no major topical and none sys-
temic side-effects. Patients were satisfied with the ther-
apy if it is efficient and if they had none or only minor
topical side effects, burning, or hyperemia. All 40 pa-
tients finished the study. The Friedman´s CHI square
and Wilcoxon test were used for statistical analysis. A




The focus of the intraocular pressure analysis was any
change in intraocular pressure when travoprost 0.004%/
timolol 0.5% fixed combination was substituted for one
of four common intraocular pressure-lowering medica-
tion(s). In this group of 40 patients (79 eyes), therapeutic
regimens prior to the travoprost 0.004%/timolol 0.5%
fixed combination substitution were as follows: timolol
0.5% monotherapy (14 eyes); betaxolol 0.5% monothe-
rapy (14 eyes); latanoprost 0.005% monotherapy (28
eyes); travoprost 0.004% monotherapy (23 eyes). At the
baseline visist, mean intraocular pressure value was
22.1±2.87 mm Hg. After 1 month, mean intraocular pres-
sure value was 15.92±1.85 mm Hg (reduction for 21.66%).
At the visit after 3 month, the mean intraocular pressure
was 15.67±2.17 mm Hg (reduction 21.14%). 3 month af-
ter dosing regimen changed to AM (6 month after begin-
ning of travoprost 0.004%/timolol 0.5% combination the-
rapy), mean intraocular pressure value was 16.28±1.59
mm Hg (19.86% reduction). The differences (mean±stan-
dard deviation) in intraocular pressure values after 1, 3
nad 6 month were all highly statistically significant (p<
0.001) compared to baseline values. Figure 1 provides a
summary of the intraocular pressure changes observed
after the substitution of travoprost 0.004%/timolol 0.5%
for the previous antiglaucoma therapy in 6 months pe-
riod. Figure 2 shows comparison of intraocular pressure
mean values between two dosing regimens of travoprost
0.004%/timolol 0.5%: in the evenning (PM) and in the
morning (AM) after 3 month therapy with each dosing
regimen. We found no statistically significant differences
in mean intraocular pressure values comparing these
two dosing regimens.
Tolerability
Travoprost 0.004%/timolol 0.5% fixed combination
was well accepted by the patients and their doctors. We
noted mild hyperemia in 4 patients (8 eyes) after 1
month therapy, but patients were motivated to continue
with medication. After 3 months of therapy in those 4 pa-
tients hyperemia was not present any more. These 4 pa-
tients were not excluded from the study. We also report
eyelashes growth in 2 patients-4 eyes, and all success-
fully finished the study. No other side effect were noted.
On Likert scale 90% of the patients were satisfied
with therapy (5% good, 10% very good and 75 % excel-
lent) and the 90% of doctors (5% good, 10% very good and
75 % excellent) judged the tolerability of the therapy as
satisfactory after first 3 month of evening (PM) dosing
(figure 3). After next 3 month, when dosing regimen
changed to morning (AM) administration, 95% patients
were satisfied with therapy (10% very good and 85% ex-
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Fig. 1. Intraocular pressure values during 6 months of travoprost
0.004 / timolol 0.5% fixed combination therapy – difference from
baseline and at 1.3 and at 6 months was statistically significant.
IOP= mean intraocular pressure, m= month, p<0.001, Fried-
man’s c2=136.
Fig. 2. Evening and morning dosing of travoprost 0.004%/timo-
lol 0.5% fixed combination– comparison of mean intraocular
pressure values after 3 months therapy of each dosing regimen.
IOP= intraocular pressure, PM=evening dosing, AM=morn-
ing dosing, no statistically significant difference, Wilcoxon test:
z=2.72, p=0.06
cellent) and 100% investigators (5% good, 20% very good
and 75 % excellent) were satisfied with the therapy (Fig-
ure 4).
Discussion
Prostaglandin analogs are today the most prescribed
antiglaucoma monotherapy because of their pottent in-
traocular pressure reduction and good tolerability. 40%
of patients treated for glaucoma are unable to achieve ad-
equate control of intraocular pressure with monothe-
rapy16 and combination of several drugs are very com-
mon. Several clinical studies that evaluate the clinical ef-
ficacy and safety of fixed combination travoprost 0.004%/
timolol 0.5% have been completed and this combination
is safe and stable20–23.The first of these by Barnebey21
was a randomized, prospective, multicenter, double-mas-
ked, parallel group study of 263 patients with either open
angle glaucoma or ocular hypertension. After a variable
washout period during which all ocular hypotensive med-
ications were held, the patients were randomized to re-
ceive either: daily (AM) fixed-combination travoprost/
timolol with vehicle (placebo) in the evening, twice daily
timolol or daily (PM) travoprost with vehicle (placebo) in
the morning. They were treated for a total of 3 months
while their intraocular pressures were monitored at nine
different time periods. Results showed that fixed-combi-
nation travoprost/timolol lowered intraocular pressure
1.9–3.3 mm Hg more that timolol alone, and 0.9–2.4 mm
Hg more than travoprost alone. The adverse event pro-
file was similar among all three study arms. Intraocular
pressure reduction from baseline ranged 32–38% for the
fixed-combination medication, compared with 29–32%
for travoprost alone and 25–30% for timolol alone. These
results suggest that fixed-combination travoprost/timo-
lol produced clinically relevant intraocular pressure re-
ductions greater than either agent alone, whereas the
incidence of adverse events was comparable.
The present study demonstrates that patients under-
going alteration in therapeutic regimen from other in-
traocular pressure lowering drugs showed a further re-
duction in intraocular pressure value. Reductions in
mean intraocular pressure from baseline up to 21.6%
were observed in the current study. Intraocular pressure
lowering effect of fixed combination travoprost 0.004%/
timolol 0.5% was superior in comparison to previous
monotherapy with betaxolol, timolol 0.5%, latanoprost
and travoprost 0.004%, during 6 month period. Reduc-
tion of intraocular pressure after administration tra-
voprost 0.004%/timolol 0.5% fixed combination therapy
was 21.66% after 1 month, 21.14% after 3 month and
19.86% after 6 month of therapy. After 3 month of PM
therapy when dosing regimen changed to AM (6 month
after beginning of travoprost 0.004%/timolol 0.5% combi-
nation therapy), mean intraocular pressure value was
16.28±1.59 mm Hg. The differences (mean±standard de-
viation) in intraocular pressure values at baseline and af-
ter 1, 3 nad 6 month were all highly statistically highly
significant (p<0.001). Recent large clinical studies such
as Ocular Hypertension Treatment Study24, the Early
Manifest Glaucoma Trial (EMGT)3, and AGIS25, have
clearly indicated the significance of lowering intraocular
pressure in preventing the development of open-angle
glaucoma in susceptible individuals and the progression
of visual field loss in those who already have the disease.
Fixed combination travoprost 0.004% and timolol 0.5%
showed endurance of intraocular pressure lowering ef-
fect in current study during observed 6 months period.
This fixed combination product may, therefore, be of
value in patients judged to be inadequately controlled on
a prostaglandin analogue or ophthalmic beta-blocker alone.
In current study the fixed combination of travoprost
0.004%/timolol 0.5% was safe and well-tolerated when
dosed either in the morning or the evening. Intraocular
pressure was sufficiently controlled after switch from
PM to AM dosing regimen after 3 month of PM therapy,
at 6 month control point. We found no statistically signif-
icant differences in mean intraocular pressure values
comparing these two dosing regimens.
Pharmacologic approach of travoprost 0.004%/timolol
0.5% fixed combination is synergistic providing different
mechanisms of action: reduce aqueous inflow by the
b-blocker and outflow improvement by prostaglandin an-
alog. Because b-blocker has reduced efficacy at night, as
well as the potential for nocturnal hypotension, this fixed
combination is likely to have better efficacy if dosed in
the daytime. Data suggest that prostaglandin analogues
may offer slightly more intraocular pressure reduction
when dosed in the evening compared to the morning26.
Konstas and colleagues27 compared AM versus PM dos-
ing of latanoprost/timolol fixed combination and found
better intraocular pressure reduction during daytime
hours when the combination was given in the evening
and better intraocular pressure reduction during night-
time hours when combination was given in the morning.
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Fig. 3. Patient´s and investivestigator´s satisfaction with travo-
prost 0.004%/timolol 0.5% fixed combination after 3 month of
PM dosing therapy.
Fig. 4. Patient´s and investigator´s satisfaction with tra-
voprost 0.004%/timolol 0.5% fixed combination after 3
month of AM dosing therapy.
Denis and collegues28 compared morning versus evening
dosing of fixed-combination travoprost/timolol in a pro-
spective, randomized study of 92 patients. After 6 weeks
of treatment, the mean intraocular pressure ranged
16.5–16.7 mmHg in the morning group, as compared
with 16.1–17.2 mmHg in the evening group. The mean
percentage of intraocular pressure reduction from base-
line in both groups was 32–38%. with no statistically sig-
nificant difference.
An important factor in the maintenance of adequate
intraocular pressure control is patient´s adherence to
prescribed treatment. Studies show that as many as 50%
of glaucoma patients do not comply with dosing instruc-
tions and that dosing frequency and convenience are im-
portant factors contributing to patient adherence28,29.
Tsai and associates7 used patient questionnaires to iden-
tify situational obstacles to medication adherence. They
found regimen factors to be an obstacle to adherence for
32% of the glaucoma patients they studied. In current
study, travoprost 0.004%/timolol 0.5% fixed combination
was well accepted by the patients and their doctors. 90%
of the patients and the doctors judged the tolerability of
the therapy as satisfactory after first 3 month of evening
(PM) dosing. After consecutive 3 month, when dosing
regimen changed to morning (AM) administration, 95%
patients and 100% investigators were satisfied with the
new therapy regimen. Patients and investigators were
also satisfied with the possibility of choosing the dosing
regimen, which has good impact on compliance and ad-
herence.
Conclusion
Well designed observational studies can identify clini-
cally important differences among therapeutical options
and provide data on drug effectiveness and safety30. In
our study intraocular pressure lowering effect of fixed
combination travoprost 0.004%/timolol 0.5%, was supe-
rior in comparison to previous monotherapy with beta-
xolol 0.5%, timolol 0.5%, latanoprost 0.005% and travo-
prost 0.004%, with statistically significant differences in
mean intraocular pressure values after 1, 3 and 6 month
of therapy. Fixed combination travoprost 0.004%/timolol
0.5% showed indurance of intraocular pressure lowering
effect in 6 month observational period, with no statisti-
cally significant differences in mean intraocular pressure
values comparing AM and PM dosing regimen. 95% pa-
tients and 100% investigators at 6 month control point
were satisfied with both, AM and PM dosing regimens,
and with the possibility of choosing the dosing regimen.
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USPOREDBA VE^ERNJEG I JUTARNJEG DOZIRANJA FIKSNE KOMBINACIJE TRAVOPROST
0,004%/TIMOLOL 0,5% S OBZIROM NA U^INKOVITOST U SNI@AVANJU O^NOG TLAKA I
ZADOVOLJSTVO BOLESNIKA LIJE^ENJEM KROZ 6 MJESECI
S A @ E T A K
Cilj istra`ivanja ove multicentri~ne, opservacijske studije je bio ustanoviti u~inkovitost u sni`avanju o~nog tlaka i
podno{ljivost (zadovoljsvtvo lijekom bolesnika i lije~nika) fiksne kombinacije travoprost 0,004%/timolol 0,5%, primije-
njene jedanput dnevno ujutro ili nave~er. 40 bolesnika (79 o~iju) sa primarnim glaukomom otvorenog kuta ili o~nom
hipertenzijom, ~iji ciljni o~ni tlak nije bio postignut monoterapijom (betaksololom, timololom 0,5%, latanoprostom i
travoprostom), po~eli su primjenjivati fiksnu kombinaciju travoprost 0,004%/timolol 0,5% jedanput dnevno nave~er,
bez »wash-out« perioda. O~ni tlak izmjeren je prije uklju~ivanja novog lije~enja kao i na kontrolnim pregledima nakon
1, 3 i 6 mjeseci, uvijek u 9 sati ujutro. Na prvom kontrolnom pregledu nakon mjesec dana, bolesnici u kojih nije do{lo do
20% sni`avanja vrijednosti o~nog tlaka, kao i bolesnici sa neugodnim popratnim pojavama lije~enja, su isklju~eni (2
bolesnika). Prilikom drugog kontrolnog pregleda nakon 3 mjeseca primjene lijeka nave~er, izmjeren je o~ni tlak i bo-
lesnici su upu}eni na primjenu lijeka ujutro, po~ev{i od slijede}eg dana, slijede}ih 3 mjeseca, nakon ~ega je vrijednost
o~nog tlaka izmjerena. Po~etna srednja vrijednost o~nog tlaka (postignuta prethodnim lije~enjem) je bila 21,13±2,18
mm Hg. Nakon 1 i 3 mjeseca primjene fiksne kombinacije travoprost 0,004%/timolol 0,5% jedanput nave~er, postignuto
je sni`enje o~nog tlaka za 21%. Promjenom na~ina primjene, davanjem lijeka ujutro kroz slijeda 3 mjeseca, srednja
vrijednost o~nog tlaka ostala je sni`ena je za 19% u odnosu prema po~etnoj vrijednosti. Razlike po~etne vrijednosti
o~nog tlaka prema vrijednostima nakon 1, 3 i 6 mjeseci su statisti~ki zna~ajne. Zadovoljstvo lije~enjem je ocijenjeno od
strane lije~nika i bolesnika nakon 3 i 6 mjeseci lije~enja, uporabom Likertove ljestvice zadovoljstva lije~enja u 5 kate-
gorija, od nezadovoljavaju}eg do odli~nog. 95% bolesnika i 100% njihovih lije~nika je bilo zadovoljno lije~enjem fiksnom
kombinacijom travoprost 0,004%/timolol 0,5%, kao i sa mogu}no{}u izbora primjene lijeka, ujutro ili nave~er, {to omo-
gu}ava individualni pristup primjene lije~enja prema potrebama bolesnika.
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